Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06566092 · ClinicalTrials.gov registry record · Phase 1
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
A Phase 1 study of Melanoma and Soft Tissue Sarcoma, sponsored by Iovance Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 5
- Study locations
NCT06566092 is a Phase 1 study of Melanoma and Soft Tissue Sarcoma that is actively recruiting participants, run by Iovance Biotherapeutics. The registered enrollment target is 40 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06566092, a Phase 1 study of Melanoma and Soft Tissue Sarcoma, is actively recruiting participants, sponsored by Iovance Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer. The study will enroll children, teenagers, and young adults with solid tumors that have returned or are not responding to treatment for whom no effective standard-of-care treatment options exist. Study details include: * The study will last up to 2 years after the TIL infusion (Day 0) for each person. * The treatment will last up to 10 days for each person. * Study visits will be every 2 weeks until Day 42, every 6 weeks until Month 6, and every 3 months until Year 2.
Conditions Studied
Interventions
- BIOLOGICAL LN-145/LN-144
Study Locations (5)
New York
- Roswell Park Cancer Institute - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
Colorado
- Children's Hospital of Colorado - Aurora
Florida
- Johns Hopkins All Children's Hospital - St. Petersburg
New Jersey
- Rutgers Cancer Institute - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06566092
The ClinicalTrials.gov registry entry for NCT06566092 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (94% lower). The listed sponsor is Iovance Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which LN-145/LN-144 is the first listed.
NCT06566092 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06566092 about?
NCT06566092 is a clinical study titled "Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants". This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer. The study will enroll children, teenagers, and young adults with solid tumors that have returned or are not responding to treatment for whom no effective standard-of-car...
What is the current status of trial NCT06566092?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-03-28. Estimated completion is 2028-07.
What conditions does trial NCT06566092 study?
This clinical trial studies the following conditions: Melanoma, Soft Tissue Sarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Primary Central Nervous System Carcinoma.
What interventions are being tested in trial NCT06566092?
The interventions under investigation include: LN-145/LN-144 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06566092?
This trial is sponsored by Iovance Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06566092 being conducted?
This trial has 5 study locations across Colorado, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.